Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer

(2019) Taiki Hakozaki et al.   Oncology Letters

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

(2019) Arielle Elkrief et al.   OncoImmunology

Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer

(2019) Sha Zhao et al.   LUNG CANCER

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer

(2019) Giulia Galli et al.   LUNG CANCER

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

(2019) Nadina Tinsley et al.   ONCOLOGIST

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

(2019) Julia Ouaknine Krief et al.   Journal for ImmunoTherapy of Cancer

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade

(2019) Huemer et al.   Journal of Clinical Medicine

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

(2019) JHE-CYUAN GUO et al.   ANTICANCER RESEARCH

Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy

(2019) Stefania Gori et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients

(2019) Xuan-Zhang Huang et al.   OncoImmunology

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

(2018) Florian Huemer et al.   Oncotarget

Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer.

(2018) Nadina Tinsley et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors

(2018) Jibran Ahmed et al.   OncoImmunology

Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials

(2018) S Sen et al.   ANNALS OF ONCOLOGY

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE